Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis.

ABSTRACT:

Importance

Cardiovascular adverse events (CVAE) with carfilzomib in patients with multiple myeloma can be potentially life-threatening and remain incompletely characterized. We performed the first systematic review and meta-analysis of carfilzomib-associated CVAE.

Objective

To determine the incidence of carfilzomib-associated CVAE and to compare the rates of carfilzomib CVAE among different doses and companion therapies.

Data sources

PubMed, EMBASE, Web of Science, and clinicaltrials.gov were queried for the keywords "carfilzomib," "Kyprolis," and "PX-171" through January 1, 2017.

Study selection

Phase 1 to 3 prospective clinical trials of carfilzomib in patients with multiple myeloma with evaluable toxic effects data were eligible for meta-analysis.

Data ex

SUBMITTER: Waxman AJ 

PROVIDER: S-EPMC5885859 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature